Agios Pharmaceuticals (AGIO) Receivables - Other (2016 - 2025)
Agios Pharmaceuticals' Receivables - Other history spans 13 years, with the latest figure at $10.6 million for Q4 2025.
- For Q4 2025, Receivables - Other rose 157.41% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, up 157.41%, while the annual FY2025 figure was $10.6 million, 157.41% up from the prior year.
- Receivables - Other reached $10.6 million in Q4 2025 per AGIO's latest filing, up from $5.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $10.6 million in Q4 2025 to a low of $540000.0 in Q1 2022.
- Average Receivables - Other over 5 years is $3.8 million, with a median of $3.2 million recorded in 2024.
- Peak YoY movement for Receivables - Other: plummeted 73.99% in 2022, then skyrocketed 229.26% in 2023.
- A 5-year view of Receivables - Other shows it stood at $7.0 million in 2021, then tumbled by 68.44% to $2.2 million in 2022, then grew by 27.38% to $2.8 million in 2023, then soared by 46.23% to $4.1 million in 2024, then soared by 157.41% to $10.6 million in 2025.
- Per Business Quant, the three most recent readings for AGIO's Receivables - Other are $10.6 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025).